Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m ethylenedicysteine amifostine - CellPoint

Drug Profile

Tc 99m ethylenedicysteine amifostine - CellPoint

Alternative Names: (99m)Tc ethylenedicysteine amifostine; 99mTc ethylenedicysteine amifostine; 99mTc-EC-amifostine; Ethylenedicysteine amifostine-Tc-99m; Technetium 99m ethylenedicysteine amifostine

Latest Information Update: 30 Mar 2020

At a glance

  • Originator CellPoint
  • Class Chemoprotectants; Diagnostic conjugates; Organotechnetium compounds; Organothiophosphorus compounds; Radiopharmaceutical diagnostics; Small molecules; Technetium compounds
  • Mechanism of Action Ionising radiation emitters; Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; COVID 2019 infections

Most Recent Events

  • 24 Mar 2020 Early research in Cancer (Diagnosis) in USA (Parenteral) before March 2020
  • 24 Mar 2020 Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020
  • 24 Mar 2020 Early research in COVID-2019 infections in USA (Parenteral) before March 2020

Development Overview

Introduction

Technetium 99m labelled ethylenedicysteine (EC) amifostine (99mTc-EC-amifostine), is a theranostic agent, being developed by Cellpoint, for detection and treatment of COVID-2019 infections as well as detection of cancers arising from viral infections by using EC drug conjugate platform. The company has in-licensed the EC platform from the M.D. Anderson Cancer Center, wherein tissue specific ligands or pharmaceutical compounds are linked to cold metals or radioisotopes. Upon targeted delivery in the organ, EC-Amifostine which is an organic thiophosphate with oxygen scavenging activity, metabolised by alkaline phosphatase (ALP) present on neutrophil surface to an active thiol analog, which scavenge free-radicals and stabilise DNA to protect the infected or organs. 99mTc-EC-amifostine can be detected using both PET and SPECT for imaging to assess location and degree of COVID-2019 infection and associated damage as well as follow-up confirmatory imaging to determine post treatment resolution. 99mTc-EC-amifostine can be used to differentiate the extent of tumour progression and the degree of viral infection involvement with tumour proliferation. Amifostine was originally developed by the Southern Research Institute in Birmingham, Alabama, USA. Early-stage development is underway in the US.

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Chemoprotectants, Diagnostic conjugates, Organotechnetium compounds, Organothiophosphorus compounds, Radiopharmaceutical diagnostics, Small molecules, Technetium compounds
  • Mechanism of Action Ionising radiation emitters; Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
  • WHO ATC code

    V09E-X (Other respiratory system diagnostic radiopharmaceuticals)

    V09H-A (Technetium (99mTc) compounds)

    V09I-A (Technetium (99mTc) compounds)

    V10A (Antiinflammatory Agents)

  • EPhMRA code

    T1G (Radiodiagnostic Agents)

    V3C (Radiopharmaceuticals)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA Parenteral / unspecified CellPoint 24 Mar 2020
COVID 2019 infections - Diagnosis Research USA Parenteral / unspecified CellPoint 24 Mar 2020
Cancer - Diagnosis Research USA Parenteral / unspecified CellPoint 24 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
CellPoint Originator USA
CellPoint Owner USA
University of Texas M. D. Anderson Cancer Center Technology Provider USA

Development History

Event Date Update Type Comment
24 Mar 2020 Phase Change Early research in Cancer (Diagnosis) in USA (Parenteral) before March 2020 Updated 30 Mar 2020
24 Mar 2020 Phase Change Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020 Updated 30 Mar 2020
24 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) before March 2020 Updated 30 Mar 2020
03 Jun 2005 Licensing Status Cellpoint in-licenses Oligosaccharide Conjugates for dual imaging and radio/chemotherapy from University of Texas M. D. Anderson Cancer Center Updated 30 Mar 2020
Back to top